MUNICH, Germany—Definiens kicked off August with the release of its Clinical Development Offering, which helps
pharmaceutical companies improve patient outcomes and reduce pipeline risk to help advance therapies to market more rapidly. This new offering features
Clinical Trial Services, Signature Discovery Services and Companion Diagnostic Services, to aid in activities such as assay development, image analysis and
biomarker discovery.

“The focus of our new Definiens clinical development offering is to support our
partners in maximizing their pipeline, to accurately identify patient populations and therefore deliver the right therapy,” said Thomas Heydler, CEO of
Definiens. “We are now providing image analysis, data mining and assay development, combined with deep scientific, regulatory and pathology support.
It’s truly an end-to-end offering for biopharma.”